Novel strategies for the early diagnosis of HBV reactivation.

Inoue, Takako; Matsui, Takeshi; Tanaka, Yasuhito

Hepatitis B virus (HBV) reactivation under systemic chemotherapy or immunosuppressive therapy is a serious complication among HBV-resolved patients. Some medications such as >2 weeks of corticosteroid therapy can influence HBV reactivation; therefore, screening tests that measure hepatitis B surface antigen (HBsAg), hepatitis B core antibody, and hepatitis B surface antibody prior to therapy are required. Additionally, because HBV reactivation has been reported in patients positive for HBsAg treated with immune checkpoint inhibitors (ICIs), the prophylactic administration of nucleos(t)ide analogues prior to administering ICIs is recommended for HBsAg-positive patients. Under these circumstances, highly sensitive novel biomarkers are expected to be used for the early diagnosis of HBV reactivation. Recently, a fully automated high-sensitive HBsAg assay (detection limit: 5 mIU/mL) by Lumipulse HBsAg-HQ, with 10-fold higher sensitivity than that of conventional assays, is currently used. Furthermore, ultra-sensitive HBsAg assays employing a semi-automated immune complex transfer chemiluminescence enzyme immunoassay (ICT-CLEIA, detection limit: 0.5 mIU/mL) have been developed. Recently, a fully automated, novel high-sensitivity hepatitis B core-related antigen assay (iTACT-HBcrAg, cut-off value: 2.1 Log U/mL) has been developing and reported. The utility of ICT-CLEIA and iTACT-HBcrAg for the diagnosis of HBV reactivation appears comparable to the use of HBV DNA. In this review, we provide the latest information related to medications that influence HBV reactivation and recently developed novel biomarkers that predict and monitor HBV reactivation. This article is protected by copyright. All rights reserved.